[F]DCFPyL PET/CT versus [F]fluoromethylcholine PET/CT in Biochemical Recurrence of Prostate Cancer (PYTHON): a prospective, open label, cross-over, comparative study.

Date publication

juin 2023

Journal

European journal of nuclear medicine and molecular imaging

Auteurs

Membres identifiés du Cancéropôle Est :
Pr OLIVIER Pierre

Tous les auteurs :
Oprea-Lager DE, Gontier E, García-Cañamaque L, Gauthé M, Olivier P, Mitjavila M, Tamayo P, Robin P, García Vicente AM, Bouyeure AC, Bailliez A, Rodríguez-Fernández A, Mahmoud SB, Vallejo-Casas JA, Maksud P, Merlin C, Blanc-Durand P, Drouet C, Tissot H, Vierasu I, Vander Borght T, Boos E, Chossat F, Hodolic M, Rousseau C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37341747

Résumé

Primary objective was to compare the per-patient detection rates (DR) of [F]DCFPyL versus [F]fluoromethylcholine positron emission tomography/computed tomography (PET/CT), in patients with first prostate cancer (PCa) biochemical recurrence (BCR). Secondary endpoints included safety and impact on patient management (PM).

Mots clés

Biochemical recurrence, PSMA PET/CT, PYLCLARI, Piflufolastat, Prostate cancer, [18F]DCFPyL

Référence

Eur J Nucl Med Mol Imaging. 2023 06 21;: